Millions of patients are diagnosed each year with acute pain conditions, whether as a result of surgery, trauma or acute illness.
ICON’s experienced neuroscience and drug development teams work with clients at all stages of clinical design and execution of trials in acute and chronic pain disorders, including autoimmune rheumatic diseases and specialised CNS teams for rare diseases and pediatric pain. This includes a collaborative, joint review of your key documents, such as Target Product Profile, Clinical Development Plan, Investigator Brochure and Regulatory Strategy materials to identify the methodologies that will best add value to your research, meet your objectives and ensure success of your pain study.
Managing placebo response
ICON has developed a unique set of materials to address the key drivers for placebo responses; patient expectations, baseline bias/inflation, and rating inconsistencies. This includes site training materials for site staff, a patient e-workbook, data analytics to manage baseline inflation, and integration of more objective endpoints which are indirectly linked to pain, for inter-scale plausibility assessment. See brochure below for more details.
ICON experience in pain studies in the last five years
60+Acute and chronic pain studies
4,000+Experienced pain sites worldwide
Whitepaper: Key considerations for trials in chronic pain
The opioid crisis has created an urgent need for innovative pain medications without the use of opioids. Unfortunately, clinical development of non-opioid pain medications, such as non-steroidal anti-inflammatory drugs (NSAIDS), has been hindered by a massive placebo-response. In this whitepaper, we discuss the aspects of pain studies that sponsors will need to consider to ensure success of their chronic pain trial model.
Accellacare experience in pain studies
284Pain studies conducted
Accellacare, ICON's dedicated global site network, has strong back pain, fibromyalgia, migraine, neuropathic pain and post herpetic neuralgia experience in particular, and provides a range of services for both ICON and sponsor-direct studies:
Endpoint quality strategies
ICON has all relevant services for wet, imaging and digital biomarker endpoints in house.
Since soft endpoints are still crucial in pain studies, ICON recommends implementing these in a way that maximises the reliability of the generated data. ICON is the leading sponsor of Mapi Research Trust, a non-profit organization and license holder of over 4,360 COAs including 274 pain related instruments and the official distributor of 26 COAs in pain indications, including some of the most commonly used as efficacy endpoints. ICON Clinical Outcomes Assessment (COA) experts have the world's largest database of PRO and other clinical outcomes assessments (COA), work in over 300 langauges, and will support you at all stages of development, from endpoint selection and Patient Reported Outcomes (PRO) development, to use in clinical trials, through post-approval work and publications.
To address the potential weaknesses of subjective pain endpoints, ICON provides an end-to-end approach to effective integration of wearable devices into trial design, execution and reporting. ICON's end-to-end framework for digital endpoints including digital biomarkers, has been used in over 40 studies.
Medical Imaging for pain studies
Disease which causes pain and severe discomfort for patients that worsens as the disease progresses includes arthropathies, such as osteoarthritis, rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis. Imaging, in particular x-rays and magnetic resonance imaging, plays a large role in the objective evaluation of joint structure for disease modifying anti-rheumatic drugs and pain relieving drugs. ICON Medical Imaging routinely provides expert imaging services for acute and chronic pain trials, using subspecialty, primarily academic radiologists as readers.
Adaptive design for pain trials
Often short treatment periods in pain studies easily allow for adaptive designs to accelerate the development.
CNS, pain and ageing related disorders insights
ICON's experienced neuroscience and drug development teams regularly share their insights in industry publications and through ICON produced content in the form of blogs and whitepapers. Read more content from our experts.Read more